March 8, 2026 •
The 'Breakthrough' Narrative: Simufilam's Phase 2b Data and Market Reaction The story of Cassava Sciences and its Alzheimer’s drug, simufilam, begins not with a discovery,…
February 25, 2026 •
Credential Stuffing Mechanics: Exploiting Recycled Login Credentials The mechanics of the October 2023 cyberattack on 23andMe represent a catastrophic failure of basic digital hygiene, not…
February 24, 2026 •
Strategic Framework: Deconstructing Bayer's 'Five-Point Plan' for Litigation Containment SECTION 1 of 14: Strategic Framework: Deconstructing Bayer’s ‘Five-Point Plan’ for Litigation Containment Bayer AG’s legal…
February 22, 2026 • Ekalavya Hansaj
The 'Points Program': Gamifying Prescriptions in China's Public Hospitals Corporate corruption often manifests as complex financial instruments or shell companies. In the case of Pfizer…
February 16, 2026 • Ekalavya Hansaj
IRS Transfer Pricing War: The $10.7 Billion Dispute over Puerto Rico Profits The IRS Transfer Pricing War: The $10.7 Billion Dispute over Puerto Rico Profits…
February 13, 2026 • Ekalavya Hansaj
The Zyprexa Papers: A $1.4 Billion Off-Label Marketing Settlement The following investigative review examines the 2009 Zyprexa settlement involving Eli Lilly and Company. The Settlement…
February 11, 2026 • Ekalavya Hansaj
Antitrust Warfare: The Metsera 'Killer Acquisition' Lawsuit Against Novo Nordisk The acquisition of Metsera Inc. stands as a defining moment in Pfizer’s corporate history during…
Enter the 14-digit code sent to your email.